Current Research Studies

Cancer – AREN1721: Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma Across All Age Groups

Condition or Therapy:

TFE/translocational renal cell carcinoma


Cancer and Blood Disorders
Study Number: AREN1721

What is the goal of this study?

This phase 2 trial studies how well axitinib and nivolumab works in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body.

Who can join the study?

This study may be a good fit for children and young adults who:

  • are older than 12 months, and
  • Have been diagnosed with translocation morphology renal cell carcinoma.

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins